Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its ...

Highlights:Meridian has engaged Ausenco do Brasil Engenharia Ltda. (Ausenco) to undertake a definitive feasibility study ("DFS") of the Cabaçal Au-Cu project;DFS targeted to be completed prior to the ...

New ASX gold developers emerge as inflation eases and record gold prices draw attention to the "rivers of cash" their ...

Kyle Murphy, P.E. of RESPEC - open pit design, mine planning, scheduling and costing ...

Q1 2025 Earnings Call Transcript May 6, 2025 Operator: Hello, everyone. And welcome to Arcus Biosciences First Quarter 2025 Earnings and Financial Results Call. My name is Lydia, and I’ll be your ...

MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...